Meet Dr. GPCR Summit Partners
- Click to Explore -
Advancing GPCR drug discovery with bioSensAll® platform technology
Wednesday, 09/15/2021 @ 10:00 PM - EST
- Dr. Meriem Semache -
- Domain Therapeuticse -
- Montréal, Québec, Canada -
Abstract
Dr. Meriem Semache, a scientist at Domain Therapeutics NA, will provide an overview on bioSensAll®, an enhanced bystander bioluminescence resonance energy transfer (ebBRET)- based biosensor technology that addresses bottlenecks limiting current GPCR drug discovery and development efforts. Presenting various case studies, Meriem will expose how novel GPCR pharmacology using small molecules and antibodies can be revealed by this biosensor technology to advance drug discovery, expand the current GPCR target space, and ultimately unlock untapped therapeutic potential for this complex and druggable class of receptors.
About Dr. Meriem Semache
Dr. Meriem Semache is a Scientist at Domain Therapeutics North America. Meriem holds a Ph.D. Degree from Université de Montréal’s department of Biochemistry. Her thesis work was focused on the mechanisms underlying the regulation of insulin gene expression and pancreatic β-cell function. Following her doctoral degree, Meriem joined the laboratory of Michel Bouvier at the Institute for Research in Immunology and Cancer of the Université de Montréal for a post-doctoral training where she worked on the profiling of the signaling signature of various G protein-coupled receptors (GPCRs) using the bioSensAll® technology. Meriem joined Domain Therapeutics North America in March 2019 where she works on various projects on GPCRs using the bioSensAll® platform.
Author list and affiliations
- Dr. Meriem Semache, Scientist at Domain Therapeutics NA
Dr. Meriem Semache on the web
Meet Dr. GPCR Summit Partners
- Click to Explore -
